Cargando…
Cannabinoid-Based Ocular Therapies and Formulations
The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146987/ https://www.ncbi.nlm.nih.gov/pubmed/37111563 http://dx.doi.org/10.3390/pharmaceutics15041077 |
_version_ | 1785034708453687296 |
---|---|
author | Saraiva, Sofia M. Martín-Banderas, Lucía Durán-Lobato, Matilde |
author_facet | Saraiva, Sofia M. Martín-Banderas, Lucía Durán-Lobato, Matilde |
author_sort | Saraiva, Sofia M. |
collection | PubMed |
description | The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to cannabinoids’ unfavorable physicochemical properties and adverse systemic effects, along with ocular biological barriers to local drug administration, drug delivery systems are needed. Hence, this review focused on the following: (i) identifying eye disease conditions potentially subject to treatment with cannabinoids and their pharmacological role, with emphasis on glaucoma, uveitis, diabetic retinopathy, keratitis and the prevention of Pseudomonas aeruginosa infections; (ii) reviewing the physicochemical properties of formulations that must be controlled and/or optimized for successful ocular administration; (iii) analyzing works evaluating cannabinoid-based formulations for ocular administration, with emphasis on results and limitations; and (iv) identifying alternative cannabinoid-based formulations that could potentially be useful for ocular administration strategies. Finally, an overview of the current advances and limitations in the field, the technological challenges to overcome and the prospective further developments, is provided. |
format | Online Article Text |
id | pubmed-10146987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101469872023-04-29 Cannabinoid-Based Ocular Therapies and Formulations Saraiva, Sofia M. Martín-Banderas, Lucía Durán-Lobato, Matilde Pharmaceutics Review The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to cannabinoids’ unfavorable physicochemical properties and adverse systemic effects, along with ocular biological barriers to local drug administration, drug delivery systems are needed. Hence, this review focused on the following: (i) identifying eye disease conditions potentially subject to treatment with cannabinoids and their pharmacological role, with emphasis on glaucoma, uveitis, diabetic retinopathy, keratitis and the prevention of Pseudomonas aeruginosa infections; (ii) reviewing the physicochemical properties of formulations that must be controlled and/or optimized for successful ocular administration; (iii) analyzing works evaluating cannabinoid-based formulations for ocular administration, with emphasis on results and limitations; and (iv) identifying alternative cannabinoid-based formulations that could potentially be useful for ocular administration strategies. Finally, an overview of the current advances and limitations in the field, the technological challenges to overcome and the prospective further developments, is provided. MDPI 2023-03-27 /pmc/articles/PMC10146987/ /pubmed/37111563 http://dx.doi.org/10.3390/pharmaceutics15041077 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saraiva, Sofia M. Martín-Banderas, Lucía Durán-Lobato, Matilde Cannabinoid-Based Ocular Therapies and Formulations |
title | Cannabinoid-Based Ocular Therapies and Formulations |
title_full | Cannabinoid-Based Ocular Therapies and Formulations |
title_fullStr | Cannabinoid-Based Ocular Therapies and Formulations |
title_full_unstemmed | Cannabinoid-Based Ocular Therapies and Formulations |
title_short | Cannabinoid-Based Ocular Therapies and Formulations |
title_sort | cannabinoid-based ocular therapies and formulations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146987/ https://www.ncbi.nlm.nih.gov/pubmed/37111563 http://dx.doi.org/10.3390/pharmaceutics15041077 |
work_keys_str_mv | AT saraivasofiam cannabinoidbasedoculartherapiesandformulations AT martinbanderaslucia cannabinoidbasedoculartherapiesandformulations AT duranlobatomatilde cannabinoidbasedoculartherapiesandformulations |